
OpenEvidence
Launched during the Mayo Clinic Platform Accelerate program and featured by the New England Journal of Medicine AI, OpenEvidence is the world’s leading medical AI.
Growth Trajectory
OpenEvidence shows growth potential through continuous AI development for improved content delivery, expansion through licensing agreements with third parties, and potential acquisitions of other companies. They also can expand by offering new specialized medical content, data enrichment, and advertising optimization. Their focus on personalized content delivery positions them well for continued expansion within the healthcare information space.
Technical Challenges
Tech Stack
Team Size
Key Risks
Opportunities
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats